Omega announced that the Company has received approval from the Federal Ministry of Health to enable the VISITECT® CD4 350 test to be deployed in Nigeria. Following a product evaluation in six geopolitical zones in Nigeria, co-ordinated by the National AIDS and Sexually Transmitted Infections Control Programme, NASCP recommended to the MOH that the Company's VISITECT® CD4 350 test be adopted into the National HIV Control Programme as a rapid and instrument-free test device that provides actionable results at the point of care. MOH approval means the Company's VISITECT® CD4 350 test is the first rapid and instrument-free CD4 test to be implemented throughout Nigeria in the care of people living with HIV.